Novo Nordisk Completes Phase 3a Trials Comparing Faster-Acting Insulin, Both Trials Achieved Primary Objectives, Treatment Non-Inferior To Novorapid

Novo Nordisk today announced headline results from the final phase 3a trials for faster-acting insulin aspart, onset^® 1 and onset^® 2. The trials investigated the efficacy and safety of faster-acting insulin aspart compared with NovoRapid^® (insulin aspart) in a basal-bolus regimen in people with type 1 and type 2 diabetes, respectively.